255 related articles for article (PubMed ID: 30663278)
1. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort.
Mondi A; Cozzi-Lepri A; Tavelli A; Rusconi S; Vichi F; Ceccherini-Silberstein F; Calcagno A; De Luca A; Maggiolo F; Marchetti G; Antinori A; d'Arminio Monforte A;
J Int AIDS Soc; 2019 Jan; 22(1):e25227. PubMed ID: 30663278
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients.
Rodriguez-Gonzalez CG; Chamorro-de-Vega E; Ortega-Navarro C; Alonso R; Herranz-Alonso A; Sanjurjo-Saez M
Ann Pharmacother; 2020 Jul; 54(7):633-643. PubMed ID: 31910643
[No Abstract] [Full Text] [Related]
3. Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort.
Ciccullo A; Baldin G; Borghi V; Lagi F; Latini A; d'Ettorre G; Oreni L; Fusco P; Capetti A; Fabbiani M; Giacomelli A; Grimaldi A; Madeddu G; Sterrantino G; Mussini C; Di Giambenedetto S
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062367
[TBL] [Abstract][Full Text] [Related]
4. Switch to dolutegravir is well tolerated in Thais with HIV infection.
Goh OQ; Colby DJ; Pinyakorn S; Sacdalan C; Kroon E; Chan P; Chomchey N; Kanaprach R; Prueksakaew P; Suttichom D; Trichavaroj R; Spudich S; Robb ML; Phanuphak P; Phanuphak N; Ananworanich J;
J Int AIDS Soc; 2019 Jul; 22(7):e25324. PubMed ID: 31294931
[TBL] [Abstract][Full Text] [Related]
5. A Phase-IV Non-interventional Study to Assess Virological Effectiveness, Safety, and Tolerability of DTG-based Antiretroviral Therapy in HIV-1 Infected Indian Persons Living with HIV.
Ashta KK; Arora S; Khanna R; Raman N; Anilkumar A; Mohan C
Curr HIV Res; 2024; 22(1):31-46. PubMed ID: 38284697
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study.
D'arminio Monforte A; Tavelli A; Sala M; Mondi A; Rusconi S; Antinori S; Puoti M; Celesia BM; Taramasso L; Saracino A; Antinori A; Cozzi-Lepri A;
J Antimicrob Chemother; 2023 Apr; 78(4):933-945. PubMed ID: 36775983
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent single-tablet regimen in a multicentre cohort in Spain.
Suárez-García I; Alejos B; Ruiz-Algueró M; García Yubero C; Moreno C; Bernal E; Pérez-Is L; Zubero Z; de Zárraga Fernández MA; Samperiz Abad G; Jarrín I;
J Int AIDS Soc; 2021 Jul; 24(7):e25758. PubMed ID: 34291580
[TBL] [Abstract][Full Text] [Related]
8. Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study.
Taramasso L; De Vito A; Ricci ED; Orofino G; Squillace N; Menzaghi B; Molteni C; Gulminetti R; De Socio GV; Pellicanò GF; Sarchi E; Celesia BM; Calza L; Rusconi S; Valsecchi L; Martinelli CV; Cascio A; Maggi P; Vichi F; Angioni G; Guadagnino G; Cenderello G; Dentone C; Bandera A; Falasca K; Bonfanti P; Di Biagio A; Madeddu G;
AIDS Patient Care STDS; 2021 Sep; 35(9):342-353. PubMed ID: 34524918
[TBL] [Abstract][Full Text] [Related]
9. Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy.
Gagliardini R; Gianotti N; Maggiolo F; Cozzi-Lepri A; Antinori A; Nozza S; Lapadula G; De Luca A; Mussini C; Gori A; Saracino A; Andreoni M; Monforte AD;
Int J Antimicrob Agents; 2021 Oct; 58(4):106406. PubMed ID: 34293454
[TBL] [Abstract][Full Text] [Related]
10. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study.
Asare K; Sookrajh Y; van der Molen J; Khubone T; Lewis L; Lessells RJ; Naidoo K; Sosibo P; van Heerden R; Garrett N; Dorward J
Lancet Glob Health; 2024 Feb; 12(2):e282-e291. PubMed ID: 38142692
[TBL] [Abstract][Full Text] [Related]
12. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
Hidalgo-Tenorio C; Cortés LL; Gutiérrez A; Santos J; Omar M; Gálvez C; Sequera S; Jesús SE; Téllez F; Fernández E; García C; Pasquau J
Medicine (Baltimore); 2019 Aug; 98(32):e16813. PubMed ID: 31393412
[TBL] [Abstract][Full Text] [Related]
13. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
Trottier B; Lake JE; Logue K; Brinson C; Santiago L; Brennan C; Koteff JA; Wynne B; Hopking J; Granier C; Aboud M
Antivir Ther; 2017; 22(4):295-305. PubMed ID: 28401876
[TBL] [Abstract][Full Text] [Related]
14. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
Santevecchi BA; Miller S; Childs-Kean LM
Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort.
d'Arminio Monforte A; Tavelli A; Di Biagio A; Sarmati L; Marchetti GC; Bai F; Cingolani A; Quiros Roldan E; Mussini C; Lichtner M; Vergori A; Piconi S; Orofino G; Fusco FM; Bandera A; Nozza S; Castagna A; Antinori A;
J Antimicrob Chemother; 2024 Jun; 79(6):1279-1288. PubMed ID: 38581349
[TBL] [Abstract][Full Text] [Related]
16. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP
Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, Convenience, Safety and Durability of DTG-Based Antiretroviral Therapies: Evidence from a Prospective Study by the Italian MaSTER Cohort.
Fusco P; Nasta P; Quiros-Roldan E; Tondinelli A; Costa C; Fornabaio C; Mazzini N; Prosperi M; Torti C; Carosi G
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112904
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study.
Baldin G; Ciccullo A; Capetti A; Rusconi S; Sterrantino G; Cossu MV; Giacomelli A; Lagi F; Latini A; Bagella P; De Luca A; Di Giambenedetto S; Madeddu G
HIV Med; 2019 Feb; 20(2):164-168. PubMed ID: 30457197
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis.
Lagi F; Botta A; Kiros ST; Meli M; Borchi B; Cavallo A; Pozzi M; Bartoloni A; Sterrantino G
Int J Antimicrob Agents; 2022 Jan; 59(1):106465. PubMed ID: 34699933
[TBL] [Abstract][Full Text] [Related]
20. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.
d'Arminio Monforte A; Cozzi-Lepri A; Di Biagio A; Marchetti G; Lo Caputo S; Rusconi S; Gianotti N; Mazzotta V; Mazzarello G; Costantini A; Castagna A; Antinori A;
J Antimicrob Chemother; 2019 May; 74(5):1363-1367. PubMed ID: 30698801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
